Identification and Validation of a Predictive Serological Biomarker Signature for Therapeutic Response to Anti-TNF, Vedolizumab, and Ustekinumab KU Leuven
Our goal is to identify biomarkers in the blood that will predict therapeutic response to biologic drugs used for the treatment of Crohn's disease(CD) patients to achieve a more individualized and effective treatment strategy and improve chances of therapeutic success prior to initiation of therapy.